Immunitybio

Immunitybio Financing Cash Flow

The Net Financing Cash Flow of Immunitybio (IBRX) as of Oct 20, 2026 is 400.24 M USD. In the previous year, Net Financing Cash Flow was 281.63 M USD — a change of 42.12% (higher).

Financing Cash Flow

400.24 MUSD

YoY

42.12%

Last updated:

Net Financing Cash Flow of Immunitybio is 2025 400.24 M USD. Net Financing Cash Flow of Immunitybio was 2024 281.63 M USD. It decreases by 42.12% higher compared to the previous year.

The Immunitybio Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2018
-771,000.00 USD
Jan 1, 2019
114.28 M USD
Jan 1, 2020
150.68 M USD
Jan 1, 2021
505.44 M USD
Jan 1, 2022
233.61 M USD
Jan 1, 2023
558.34 M USD
Jan 1, 2024
281.63 M USD
Jan 1, 2025
400.24 M USD
The Immunitybio Financing Cash Flow history
YEARFinancing Cash FlowYoY
400.24 MUSD+42.12%
281.63 MUSD-49.56%
558.34 MUSD+139.00%
233.61 MUSD-53.78%
505.44 MUSD+235.45%
150.68 MUSD+31.85%
114.28 MUSD-14,922.18%
-771,000.00USD-97.80%
-34.98 MUSD+124.83%
-15.56 MUSD-104.90%
317.33 MUSD+392.70%
64.41 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Immunitybio Stock analysis

What does Immunitybio do? Translate this as near as possible to English. ImmunityBio Inc is a biotechnology company specializing in innovative methods to combat cancer and other serious diseases. The company was founded in 2015 by esteemed biotech entrepreneur and scientist, Dr. Patrick Soon-Shiong. The idea behind ImmunityBio was to create a company focused on developing advanced immunotherapies that involve the human immune system in the fight against cancer. The business model is based on several business units, including research and development, diagnostics, and therapeutics. In recent years, the company has expanded through a series of significant acquisitions and mergers, including CytRx Corporation, NantWorks LLC, and NantKwest Inc. Together, these mergers have expanded and united the resources and expertise of ImmunityBio to achieve new advancements in oncology. ImmunityBio has also developed a variety of products focused on strengthening the immune system, including its leading drug, INT-001, intended for the treatment of lung, pancreatic, breast, stomach, and colorectal cancer. The company has also developed diagnostic products, such as the ImmuneMap™ test, which analyzes the patient's immune profile and can contribute to better combinations of existing immunotherapies. Another business unit is the service department, which focuses on providing services related to precision medicine. ImmunityBio offers a wide range of personalized drugs and services to help provide patients with better and more effective treatment. The company also has an extensive pipeline of immunotherapies for various indications, including several clinical trials for the treatment of lung cancer, pancreatic cancer, and breast cancer. The portfolio includes both single agents and combination therapies, which the company will introduce after a rigorous phase 1 study. Overall, ImmunityBio has an ambitious goal of being a leading player in the innovation of immunotherapies. Through a multidisciplinary approach to the discovery and development of new treatments, ImmunityBio is working to defeat cancer by strengthening the immune system and improving the quality of life for patients worldwide. Immunitybio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Immunitybio stock

Net Financing Cash Flow of Immunitybio is 400.24 M USD in 2025.

Net Financing Cash Flow of Immunitybio changed from 281.63 M USD to 400.24 M USD, representing a 42.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Immunitybio since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Immunitybio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Immunitybio

All Key Metrics — Immunitybio